April 25-29: Who said What in Biotech and Pharmaceutical Industries?


In past week, (almost) every news that we published was embellished with a promise that researchers and scientists made regarding their business and innovation and a hope that the collaborators filled us with to take R&D to a level higher and benefit the human race, so let us check out who said what…

Quote 1.

“With the advent of next generation sequencing and the increased sophistication of data analysis, the time is now right to immerse ourselves fully in the international genomics community through these pioneering collaborations and through the creation of our own genome centre”.Who said it? Answer is here

Quote 2.

“Now, what if instead of taking so much pain in treatment of malaria we could eradicate the vector of the disease- No Mosquito-No Malaria”.Who said it? Answer is here

Quote 3.

“Novartis is in a time of need, having had setbacks with both Alcon and Entresto, and investor sentiment is languishing”.Who said it? Answer is here

Quote 4.

“We are delighted to work with the Hummingbird team to explore this highly innovative approach to developing therapeutic antibodies which potentially could significantly improve the time and cost of developing new biotherapeutics”.Who said it? Answer is here

Quote 5.

“This approval is especially significant because patients with chronic HCV with compensated cirrhosis are among the tough to treat, and in our study VIEKIRA PAK demonstrated 100 percent cure rates in GT1b patients without the use of ribavirin”.Who said it? Answer is here

Quote 6.

“Rare diseases are the perfect targets for our unbiased, target-agnostic discovery platform as relatively little is known about these conditions. Our application of cutting edge machine-learning technology allows us to leverage experiments across biology to enable identification of new indications for our partners”.Who said it? Answer is here

Quote 7.

“We are excited by these results, as they suggest that TDO and KMO inhibition could be a general strategy employed to improve symptoms in a myriad of neurodegenerative disorders, not just Parkinson’s and Alzheimer’s. Indeed, five years ago we first showed that these manipulations could improve “symptoms” in Huntington’s disease model flies, so our next step is to validate our work in mammalian models and ultimately to see if such drugs could be helpful to patients in clinical trials”.-Who said it? Answer is here

Quote 8.

“We are delighted to extend our collaboration with the USFDA after starting our collaboration back in 2008. With over 80,000 Biomarkers and more importantly the content and coverage of the database, we hope that the utility of the database to the NCTR and the Reviewers at the USFDA is further maximized”.Who said it? Answer is here

Quote 9.

“There is no other more suitable time for a wake-up call to gear up and propel India’s life sciences sector onto a trajectory of rapid development”.Who said it? Answer is here

Quote 10.

We are pleased with the success of our collaboration with Adimab. The versatility and quality of the Adimab platform have been instrumental in supporting our CAR-T cell therapies beyond KTE-C19″.-Who said it? Answer is here

Quote 11.

We’re pleased to be entering into this agreement with Ironwood, a company with whom we already have a number of successful commercial partnerships. Our new agreement with Ironwood will ensure the successful launch of Zurampic in the US, while allowing us to concentrate our resources on the innovative medicines in our main therapy areas”.Who said it? Answer is here

Leave a reply

Your email address will not be published. Required fields are marked *